Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Overall Survival
100%
Breast Cancer
84%
Disease Free Survival
68%
Progression Free Survival
55%
Prognostic Factor
54%
Lymphocyte
47%
Mean Platelet Volume
45%
Multivariate Analysis
42%
Metastatic Breast Cancer
41%
Hormone Receptor
33%
Pancreas Cancer
33%
Trastuzumab Deruxtecan
33%
Malignant Neoplasm
32%
Platelet
30%
Hazard Ratio
27%
Neutrophil
24%
Gamma Urogastrone
23%
Primary Tumor
19%
Lung
19%
Epidermal Growth Factor Receptor 2
19%
Tumor
19%
Adverse Event
17%
Thrombocyte Activation
17%
Proportional Hazards Model
17%
Disease Exacerbation
16%
Cyclin-Dependent Kinase
16%
Lymph Node
16%
Gastroesophageal Junction
16%
Larynx Carcinoma
16%
Lung Cancer
16%
Cancer Recurrence
16%
Sorafenib
16%
Laryngeal Cancer
16%
Tumor Localization
16%
Finger
16%
Triple Negative Breast Cancer
16%
Cetuximab
16%
Blood Group
16%
Meta-Analysis
16%
Hepatocellular Carcinoma
16%
Gastritis
16%
Colorectal Carcinoma
16%
Ulcer
16%
Androgenic Alopecia
16%
Hypertrichosis
16%
Ribociclib
16%
Palbociclib
16%
Impaired Glucose Tolerance
16%
Exemestane
16%
Everolimus
16%
Pharmacology, Toxicology and Pharmaceutical Science
Progression Free Survival
71%
Trastuzumab
52%
Overall Survival
43%
Chemotherapy Regimens
43%
Epidermal Growth Factor Receptor 2
35%
Gamma Urogastrone
35%
Breast Cancer
35%
Metastatic Breast Cancer
34%
Abdominal Cancer
33%
Everolimus
20%
Taxane
19%
Malignant Neoplasm
19%
Disease Exacerbation
18%
Gastritis
16%
Liver Cell Carcinoma
16%
Ulcer
16%
Regorafenib
16%
Membrane Metalloendopeptidase
16%
Cetuximab
16%
Substance P
16%
Vasoactive Intestinal Polypeptide
16%
Hormone Receptor
16%
Capecitabine
16%
Trastuzumab Emtansine
16%
Pertuzumab
16%
Exemestane
16%
Ribociclib
16%
Palbociclib
16%
Alopecia
16%
Hypertrichosis
16%
Endocrine Therapy
16%
Bevacizumab
16%
Tolerability
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Ovary Cancer
16%
Trastuzumab Deruxtecan
16%
Intracranial Tumor
16%
Niraparib
12%
Olaparib
10%
Monotherapy
9%
Survival Rate
7%
Sorafenib
6%
Oxaliplatin
6%
Stomach Adenocarcinoma
6%
Irinotecan
5%
Adverse Event
5%
Neutropenia
5%
Survival Time
5%
Keyphrases
Subsequent Therapy
33%
Inflammatory Index
33%
Overall Survival
26%
Cancer Patients
24%
In Cancer
20%
Trastuzumab
19%
Human Epidermal Growth Factor Receptor 2 (HER2)
19%
Progression-free Survival
16%
Metastatic Breast Cancer
16%
Disease Progression
16%
Hormone-positive
16%
Cyclin-dependent Kinase 4 (CDK4)
16%
Advanced Breast Cancer
16%
Inhibitor Therapy
16%
Hormone Receptor-positive
16%
Mean Platelet Volume
16%
Platelet Activation
16%
Prognostic Score
16%
Impaired Glucose Tolerance
16%
Gastroesophageal Junction Tumors
16%
Positive-negative
16%
HER2-negative Breast Cancer
16%
Patients with Colorectal Cancer
16%
Blood Group
16%
Real-life Analysis
16%
Older Patients with Breast Cancer
16%
Author Names
16%
Trichomegaly
16%
Lymph Node Ratio
16%
Depression Score
16%
Primary Sjgren Syndrome
16%
Patients Receiving Chemotherapy
16%
T-DM1
16%
Pertuzumab
16%
Trastuzumab Emtansine
16%
Previously Treated
16%
Depression Severity
16%
Gastroesophageal Junction Cancer
16%
Mean Platelet Volume-to-lymphocyte Ratio
16%
Prognostic Indicator
16%
Esophageal Cancer Surgery
16%
HER2-low
16%
Removed Lymph Nodes
16%
Acrometastasis
16%
Laryngeal Carcinoma
16%
Prognostic Role
16%
Fear of Cancer Recurrence
16%
World Data
16%
Treatment Lines
16%
Capecitabine Maintenance
16%
